JP2013518882A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518882A5
JP2013518882A5 JP2012551997A JP2012551997A JP2013518882A5 JP 2013518882 A5 JP2013518882 A5 JP 2013518882A5 JP 2012551997 A JP2012551997 A JP 2012551997A JP 2012551997 A JP2012551997 A JP 2012551997A JP 2013518882 A5 JP2013518882 A5 JP 2013518882A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
medicament
day
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012551997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/022216 external-priority patent/WO2011097087A1/en
Publication of JP2013518882A publication Critical patent/JP2013518882A/ja
Publication of JP2013518882A5 publication Critical patent/JP2013518882A5/ja
Withdrawn legal-status Critical Current

Links

JP2012551997A 2010-02-05 2011-01-24 JAK阻害剤としてのピロロ[2,3−d]ピリミジン尿素化合物 Withdrawn JP2013518882A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30191510P 2010-02-05 2010-02-05
US61/301,915 2010-02-05
PCT/US2011/022216 WO2011097087A1 (en) 2010-02-05 2011-01-24 Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors

Publications (2)

Publication Number Publication Date
JP2013518882A JP2013518882A (ja) 2013-05-23
JP2013518882A5 true JP2013518882A5 (enExample) 2014-03-13

Family

ID=43629121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012551997A Withdrawn JP2013518882A (ja) 2010-02-05 2011-01-24 JAK阻害剤としてのピロロ[2,3−d]ピリミジン尿素化合物

Country Status (9)

Country Link
US (1) US20120309776A1 (enExample)
EP (1) EP2531508A1 (enExample)
JP (1) JP2013518882A (enExample)
CN (1) CN102822177A (enExample)
AU (1) AU2011213198B2 (enExample)
BR (1) BR112012019511A2 (enExample)
CA (1) CA2788071A1 (enExample)
MX (1) MX2012009074A (enExample)
WO (1) WO2011097087A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
WO2014043257A1 (en) * 2012-09-12 2014-03-20 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
BR112015029463B1 (pt) * 2013-06-07 2023-01-10 Jiangsu Hengrui Medicine Co.,Ltd. Bissulfato de inibidor da janus quinase (jak), seu uso e seu método de preparação, e composição farmacêutica
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
HUE049775T2 (hu) 2015-11-24 2020-10-28 Theravance Biopharma R&D Ip Llc Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei
JP7096592B2 (ja) * 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Jak阻害剤およびこれらの利用
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
CN110662755A (zh) 2017-05-23 2020-01-07 施万生物制药研发Ip有限责任公司 托法替尼的硫代氨基甲酸酯前药
US10745405B2 (en) 2017-05-23 2020-08-18 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of Janus kinase inhibitors
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE247469T1 (de) * 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
EP1087970B1 (en) 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3-d]嘧啶化合物
SK17342002A3 (sk) 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
ATE302751T1 (de) * 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
RS20050380A (sr) 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
US7732237B2 (en) 2005-06-27 2010-06-08 The Regents Of The University Of California Quantum dot based optoelectronic device and method of making same
ATE540952T1 (de) 2005-07-29 2012-01-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese
WO2008029237A2 (en) * 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis

Similar Documents

Publication Publication Date Title
JP2013518882A5 (enExample)
AU2011215638B2 (en) Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
JP7541594B2 (ja) PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
JP7558334B2 (ja) PI3K-γ阻害剤としてのアミノピラジンジオール化合物
KR20120120416A (ko) Mglur4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법
JP2013526544A5 (enExample)
JP2014526492A5 (enExample)
CL2011000353A1 (es) Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus.
EP2568809A1 (en) Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
JP2013514980A5 (enExample)
KR20120129869A (ko) Mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
JP2013510120A5 (enExample)
JP2012514655A (ja) フッ素含有化合物およびその使用法
HRP20200836T1 (hr) Liječenje bolesti povezanih s imunitetom i upalnih bolesti
JP2010077141A5 (enExample)
JP2011006480A5 (enExample)
KR20120115252A (ko) Mglur4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법
JP2013522326A5 (enExample)
JP2013518036A5 (enExample)
JP2013508382A5 (enExample)
WO2010129242A2 (en) Treatment of osteoarthritis pain
JP2016513124A5 (enExample)
JP2015502371A5 (enExample)
JP2014515405A (ja) オピオイド受容体アゴニストの逐次投与のための組成物
MX2010013978A (es) Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas.